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Abstract 
Background: Oculocutaneous albinism (OCA) is a clinically and genetically heterogenic group of pigmentation 
abnormalities characterized by variable hair, skin, and ocular hypopigmentation. Six known genes and a locus on 
human chromosome 4q24 have been implicated in the etiology of isolated OCA forms (OCA 1–7).
Methods: The most frequent OCA types among Caucasians are OCA1, OCA2, and OCA4. We aimed to investigate 
genes responsible for the development of these OCA forms in Hungarian OCA patients (n = 13). Mutation screening 
and polymorphism analysis were performed by direct sequencing on TYR, OCA2, SLC45A2 genes.
Results: Although the clinical features of the investigated Hungarian OCA patients were identical, the molecular 
genetic data suggested OCA1 subtype in eight cases and OCA4 subtype in two cases. The molecular diagnosis was 
not clearly identifiable in three cases. In four patients, two different heterozygous known pathogenic or predicted 
to be pathogenic mutations were present. Seven patients had only one pathogenic mutation, which was associated 
with non-pathogenic variants in six cases. In two patients no pathogenic mutation was identified.
Conclusions: Our results suggest that the concomitant screening of the non-pathogenic variants—which alone do 
not cause the development of OCA, but might have clinical significance in association with a pathogenic variant—is 
important. Our results also show significant variation in the disease spectrum compared to other populations. These 
data also confirm that the concomitant analysis of OCA genes is critical, providing new insights to the phenotypic 
diversity of OCA and expanding the mutation spectrum of OCA genes in Hungarian patients.
Keywords: Oculocutaneous albinism, Concomitant analysis, TYR gene, SLC45A2 gene, OCA2 gene
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Oculocutaneous albinism (OCA) is a clinically and 
genetically heterogenic group of rare monogenic diseases 
characterized by diffuse reduced melanin production in 
the skin, hair, and/or eyes [1]. Eye symptoms including 
photophobia, nystagmus, strabismus, foveal hypoplasia, 
reduced iris, and retinal pigmentation and reduction in 
visual acuity are present in all types of albinism. To date, 
six genes and a locus on 4q24 human chromosomal 
region have been implicated in the development of the 
isolated OCA forms (OCA 1–7) [2]. Tyrosinase gene 
(TYR; OMIM 606933) is responsible for the development 
of OCA type 1 (OCA1) [3, 4]. Mutations of the oculocu-
taneous albinism two gene (OCA2; OMIM 611409) are 
associated with OCA type 2 (OCA2) [5]. Pathogenic 
variants of the tyrosinase-related protein gene (TYRP; 
OMIM 115501) are linked with OCA type 3 (OCA3) [6]. 
Mutations in a membrane-associated transporter gene 
(SLC45A2; OMIM 606202) are implicated in OCA type 
4 (OCA4) [7]. OCA5 phenotype is linked to an unknown 
gene on human chromosome 4q24 [8]. Mutations of the 
sodium/calcium/potassium exchanger 5 gene (SLC24A5; 
OMIM 609802) encoding a solute carrier protein are 
associated with a new form of OCA, named as OCA6 [9]. 
The mutations of chromosome 10 open reading frame 
11 gene (C10ORF11; OMIM 614537) are responsible for 
OCA7 type of albinism [10]. Furthermore, an additional 
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10 genes have been associated with syndromic OCA 
variants such as Hermansky–Pudlak syndrome (HPS) 
and Chediak–Higashi syndrome (CHS) [2]. Noted, there 
is a form of albinism, ocular albinism (OA1), affecting 
the eyes, but does not affect the hair and skin, which is 
caused by the mutation in G protein-coupled receptor 
143 gene (GPR143; OMIM 300808) [11].
Oculocutaneous albinism affects approximately one in 
20,000 individuals worldwide; however, the prevalence 
of its subtypes varies among different populations [12]. 
Although OCA1, OCA2, and OCA4 are present in Cau-
casian populations, the most common form is OCA1 [6]. 
OCA3 is present in mainly Africans and is rarely seen in 
other populations [6], OCA5 has been found in one Paki-
stani family to date [8], OCA6 is recently discovered in 
one Chinese family [9] and OCA7 has been explored in 
several Faroese families (Denmark) [10].
Since the most frequent forms of OCA in Caucasian 
population are OCA1, OCA2, and OCA4, we performed 
mutation screening of the TYR, OCA2, and SLC45A2 
genes to promote the understanding of disease heteroge-
neity, to assess the independent and cumulative contri-
butions of these three genes to the disease development, 
and to compare relative and cumulative frequencies of 
disease variants in a representative Hungarian OCA 
population.
Patients and methods
Examined individuals
The individuals (n = 13) participating in this study were 
recruited at the Mór Kaposi Teaching Hospital of the 
Somogy County (Kaposvár, Hungary), at the Hospi-
tal of Zala County (Zalaegerszeg, Hungary) and at the 
Department of Dermatology and Allergology, University 
of Szeged (Szeged, Hungary). In the enrolled patients, 
the diagnosis of OCA was established in the presence 
of skin and hair hypopigmentation and distinctive ocu-
lar changes such as nystagmus, reduced iris pigmenta-
tion, reduced retinal pigmentation, and foveal hypoplasia 
(Table 1). All investigated individuals were Hungarians.
The investigation was approved by the Internal Ethi-
cal Review Board of the University of Szeged. Written 
informed consent was obtained from the patients and the 
healthy controls, and the study was conducted according 
to the Principles of the Declaration of Helsinki.
Genetic investigation
Blood was drawn from the enrolled individuals, and 
genomic DNA was isolated using a BioRobot EZ1 DSP 
Workstation (QIAGEN; Godollo, Hungary). The entire 
coding regions and the flanking introns of the TYR, 
OCA2, and SLC45A2 genes were amplified (primer 
sequences used were taken from the UCSC Genome 
Browser). Since a pseudogene of TYR, tyrosinase-like 
gene (TYRL; OMIM 191270) is known, which shows 
98.55% identity with the 3′region of TYR (exon 4 and 
5), specific primers were used for amplification of these 
regions [13]. Direct sequencing of PCR products was 
performed on an ABI 3100 sequencer and compared 
with the wild-type gene sequences using the Ensemble 
Genome Browser.
Pathogenicity predictions
As in previous study [14], in silico tools were applied 
to identify the functional impact of the newly detected 
missense mutations. Here we used SIFT (Sorting Intol-
erant from Tolerant, PolyPhen 2.0 (Polymorphism 
Phenotyping), Mutation Taster, PROVEAN (Protein Var-
iation Effect Analyzer) and PANTHER (Protein ANalysis 
THrough Evolutionary Relationships) tools. SIFT is based 
on the evolutionary conservation and predicts whether 
an amino acid substitution affects protein function. SIFT 
prediction score ranges from 0 to 1, and the amino acid 
substitution is predicted damaging if the score is less 
than an equal to 0.05, and tolerated if the score is greater 
than 0.05 [15]. PolyPhen 2.0 is based on structural and 
comparative evolutionary considerations and predicts 
the possible impact of an amino acid substitution on the 
Table 1 Clinical features of the Hungarian OCA patients
Patient Gender Age Skin Hair color Iris color
1 Male 75 Hypopigmented, no 
tanning ability
Snow-white Blue
2 Male 7 Hypopigmented, no 
tanning ability
Snow-white Blue
3 Female 57 Hypopigmented, no 
tanning ability
Snow-white Blue
4 Male 48 Hypopigmented, no 
tanning ability
Snow-white Blue
5 Female 60 Hypopigmented, no 
tanning ability
Snow-white Blue
6 Male 11 Hypopigmented, no 
tanning ability
Snow-white Blue
7 Male 15 Hypopigmented, no 
tanning ability
Snow-white Blue
8 Female 3 Hypopigmented, no 
tanning ability
Snow-white Blue
9 Female 31 Hypopigmented, no 
tanning ability
Snow-white Blue
10 Female 28 Hypopigmented, no 
tanning ability
Snow-white Blue
11 Male 21 Hypopigmented, no 
tanning ability
Snow-white Blue
12 Male 6 Hypopigmented, no 
tanning ability
Snow-white Blue
13 Male 4 Hypopigmented, no 
tanning ability
Snow-white Blue
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stability and function of a protein. PolyPhen 2.0 uses the 
same range than SIFT (0–1) and the substitution is pre-
dicted to be possibly/probably damaging at greater than 
an equal to 0.5 value [16]. Mutation Taster is a predic-
tion software based on the physicochemical properties 
of amino acids and scores substitutions according to the 
degree of difference between the original and the new 
amino acid (0–215) [17]. PROVEAN prediction is based 
on the sequence homology. If the PROVEAN score is 
equal to or below the default score threshold (−2.5), the 
protein variant is predicted to be deleterious and if the 
score is above the threshold, the variant is predicted to be 
neutral [18]. PANTHER program is a library of protein 
family and subfamily, which predicts the occurrence fre-
quency of an amino acid in evolutionary conserved pro-
tein sequences. If the score is −3 or less, the variant is 
predicted has deleterious effect [19].
Results
During the investigation of TYR, OCA2, and SLC45A2 
genes, we have identified pathogenic mutations in 84% 
(n = 11) of the examined individuals (n = 13), as shown 
in Table 2. In 4 cases, two heterozygous mutations have 
been found, suggesting a compound heterozygous state. 
Seven patients carried only one disease-causing muta-
tion. Furthermore, in 11 cases out of 13, we have detected 
one or more common polymorphisms.
Direct sequencing of the TYR gene revealed pathogenic 
mutations in 69% (n  =  9) of the investigated patients. 
Only one patient carried two heterozygous mutations, 
a Thymin-base duplication (c.74dupT, p.Ser26Leufs*2) 
and a nonsense (c.346C>T, p.Arg116*) mutation in the 
first exon of TYR gene, suggesting a compound hete-
rozygous state. Three patients carried the c.1037−7T>A 
splice site mutation in homozygous form. Out of these 
three patients, two (Patient 2 and 3) are related to each 
other and one (Patient 4) is not aware of any relationship 
with the other two mutation carriers. We have detected 
the c.1204C>T p.Arg402* nonsense mutation heterozy-
gously in one case and the c.650G>A p.Arg217Gln mis-
sense mutation heterozygously in three patients. The 
heterozygous c.1366+4A>G splice site mutation has 
been detected in one patient. This patient was addi-
tionally heterozygous for the SLC45A2 c.1099G>A 
p.Val367Ile mutation. Considering the common poly-
morphisms of TYR gene, the c.575C>A p.Ser192Tyr, and 
c.1205G>A p.Arg402Gln were detected in seven patients. 
The p.Ser192Tyr variant affects a copper-binding domain 
of the protein; all the other exonic pathogenic and non-
pathogenic variants are located outside of the known 
functional domains of the enzyme (Fig. 1a).
No pathogenic OCA2 mutation was identified in the 
investigated OCA individuals. However, one patient with 
the pathogenic c.1037−7T>A TYR mutation carried the 
common c.913C>T p.Arg305Trp polymorphism of the 
OCA2 gene in heterozygous form. This variant does not 
affect any known functional domains of the OCA2 pro-
tein (Fig. 1b).
Based on our results, 3 of 13 patients carried SLC45A2 
pathogenic mutation. Two patients carried the combi-
nation of two novel mutation previously described by 
our workgroup: the c.1226G>A p.Gly409Asp missense 
mutation and the c.1459C>T p.Gln487* nonsense muta-
tion. These mutations are not present in any SNP data-
base (ExAC, 1000 Genome Project, ClinVar). Prediction 
analyses were performed to identify the functional role of 
the missense mutation. All prediction software suggested 
that the p.Gly409Asp mutation is deleterious (SIFT score: 
0.002, damaging; PolyPhen 2.0 score: 0.996, probably 
damaging; Mutation Taster score: 94, disease causing; 
PROVEAN score: −3.25, deleterious; PANTHER score: 
−4.26, deleterious). The nonsense mutation was deemed 
to be pathogenic. One patient carried the c.1099G>A 
p.Val367Ile missense mutation beside the c.1366+4A>G 
splice site mutation on the TYR gene. In eight patients, 
only the non-pathogenic c.1122G>C p.Leu374Phe mis-
sense polymorphism was detected. All the detected path-
ogenic and non-pathogenic variants are located within 
transmembrane domains of the encoded protein (Fig. 1c).
Discussion
This study reports the concomitant investigation of three 
genes (TYR, OCA2, and SLC45A2) in 13 Hungarian OCA 
patients, which have been implicated in the development 
of isolated OCA forms. The TYR gene encodes the tyrosi-
nase enzyme, which catalyzes the first and second steps 
in melanin synthesis: the hydroxylation of tyrosine to 
l-DOPA and the oxidation of l-DOPA to DOPA-quinone 
[3]. The OCA2 and SLC45A2 genes encode transporter 
proteins, which are implicated in the trafficking of tyrosi-
nase to melanosomes [20, 21].
Pathogenic TYR mutations were present in 69% (n = 9) 
of the patients. However, the sample size of this study is 
small, our results correlate well with previous findings 
that OCA1 is the most common isolated OCA subtype 
and TYR mutations account for approximately 25–50% of 
the isolated OCA cases worldwide [6, 22].
In our study, three missense variants were detected 
for the TYR gene. One of these variants is consid-
ered pathogenic (p.Arg217Gln) and two (p.Ser192Tyr, 
p.Arg402Gln) are considered common polymorphisms. 
The p.Arg217Gln mutation is located in a non-con-
servative region of tyrosinase protein, at this amino 
acid position two other known missense mutations are 
described (p.Arg217Gly, p.Arg217Trp) [23]. The poly-
morphisms of TYR gene were not directly related to 
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Table 2 Detected TYR, SLC45A2, and OCA2 mutations and polymorphisms
Patient Mutation 1 Mutation 2 Polymorphisms Molecular 
diagnosis
1 TYR gene: c.74dupT p.Ser26Leufs*2 
(hetero)
TYR gene: c.346C>T p.Arg116* 
(hetero)
– OCA1
2 TYR gene: c.1037−7T>A (homo) – SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
OCA2 gene: c.913C>T p.Arg305Trp (hetero)
Global MAF: 0.0790
Caucasian MAF: 0.0650
OCA1
3 TYR gene: c.1037−7T>A (homo) – SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
OCA1
4 TYR gene: c.1037−7T>A (homo) – SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
OCA1
5 TYR gene: c.1204C>T p.Arg402* 
(hetero)
– TYR gene: c.575C>A p.Ser192Tyr (homo)
Global MAF: 0.1234
Caucasian MAF: 0.3718
SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
OCA1
6 TYR gene: c.650G>A p.Arg217Gln 
(hetero)
– TYR gene: c.1205G>A p.Arg402Gln (hetero)
Global MAF: 0.0813
Caucasian MAF: 0.2525
SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
OCA1
7 TYR gene: c.650G>A p.Arg217Gln 
(hetero)
– TYR gene: c.1205G>A p.Arg402Gln (hetero)
Global MAF: 0.0813
Caucasian MAF: 0.2525
SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
OCA1
8 TYR gene: c.650G>A p.Arg217Gln 
(hetero)
– – OCA1
9 SLC45A2 gene: c.1226G>A 
p.Gly409Asp (hetero)
SLC45A2 gene: c.1459C>T 
p.Gln487* (hetero)
TYR gene: c.575C>A p.Ser192Tyr (homo)
Global MAF: 0.1234
Caucasian MAF: 0.3718
TYR gene: c.1205G>A p.Arg402Gln (hetero)
Global MAF: 0.0813
Caucasian MAF: 0.2525
OCA4
10 SLC45A2 gene: c.1226G>A 
p.Gly409Asp (hetero)
SLC45A2 gene: c.1459C>T 
p.Gln487* (hetero)
TYR gene: c.575C>A p.Ser192Tyr (hetero)
Global MAF: 0.1234
Caucasian MAF: 0.3718
OCA4
11 TYR gene: c.1366+4A>G (hetero) SLC45A2 gene: c.1099G>A 
p.Val367Ile (hetero)
TYR gene: c.575C>A p.Ser192Tyr (hetero)
Global MAF: 0.1234
Caucasian MAF: 0.3718
SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
OCA1/
OCA4
12 – – TYR gene: c.575C>A p.Ser192Tyr (homo)
Global MAF: 0.1234
Caucasian MAF: 0.3718
TYR gene: c.1205G>A p.Arg402Gln (hetero)
Global MAF: 0.0813
Caucasian MAF: 0.2525
SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
Unknown
13 – – SLC45A2 gene: c.1122G>C p.Leu374Phe (homo)
Global MAF: 0.2750
Caucasian MAF: 0.0616
Unknown
MAF minor allele frequency
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pigmentation phenotypes in normal Caucasians, but 
their impact should be taken into account as an impor-
tant modifier of human skin, hair, and eye color [24]. 
Functional studies reported that 192Tyr allele reduced 
tyrosinase activity, significant reduction in heterozy-
gous and consistent decrease in homozygous form were 
observed, and the presence of 402Gln allele resulted 
significantly less TYR protein, displayed altered traf-
ficking and glycosylation, with reduced DOPA oxidase 
[24]. The p.Arg402Gln polymorphism exhibits reduced 
tyrosinase activity at physiological temperature and is 
considered a temperature-sensitive variant [25–27]. 
This variant alone is unable to cause OCA; however, 
its increased frequency in OCA patients with one het-
erozygous pathogenic TYR mutation suggests that it 
can contribute to the development of OCA in combi-
nation with a pathogenic mutation [28]. Two Hungar-
ian patients carried the p.Arg402Gln polymorphism in 
combination with the p.Arg217Gln pathogenic variant. 
Previous report suggests this combination might con-
tribute to the development of the OCA symptoms of the 
patient [26].
In one case, compound heterozygosity for two muta-
tions was found. A heterozygous T-base duplication 
(c.74dupT p.Ser26Leufs*2) and a nonsense mutation 
(c.346C>T, p.Arg116*) were identified on TYR gene. 
Both mutations lead to the development of a premature 
termination codon. Due to these changes, the translated 
mutant TYR protein is highly truncated and we assume 
that these enormous truncations of the mutant TYR pro-
tein may lead to its dysfunction.
Two of the nine Hungarian OCA patients with TYR 
mutations carry a combination of two pathogenic muta-
tions. In three of nine, a splice site mutation was iden-
tified in homozygous form. In four of nine, only one 
heterozygous pathogenic mutation was identified. These 
results correlate well with the recently reported investi-
gation of an Iranian OCA population: pathogenic TYR 
Fig. 1 a Distribution of the detected TYR variants on the tyrosinase protein, b OCA2 variant on the transporter protein, and c SLC45A2 variants on 
the transporter protein (SP signal peptide, EGF-like domain epidermal-growth-factor-like domain, CuA copper-binding domain, CuB copper-binding 
domain, TM transmembrane domain)
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variants were identified in 19 of 30 patients, and in this 
study, six patients carried only one pathogenic TYR 
mutation, and any pathogenic mutation were not identi-
fied in five patients [4].
The pathogenic TYR mutations detected in the Hun-
garian OCA patients have been previously identified in 
OCA patients of different ethnicity. The p.Arg217Gln 
mutation was detected in Caucasians from USA, Canada, 
and Northern-Europe; the p.Arg402* in Caucasians from 
Lebanon; the c.1037−7T>A in Caucasians and Japanese; 
the c.1366+4A>G in Caucasians; and the c.346C>T in 
Caucasians, Japanese, and Germans [22, 29]. The fre-
quency of pathogenic mutations differs in different popu-
lations, and, therefore, these populations might vary in 
their genetic susceptibility to certain diseases. Based on 
our results and the results of previous studies, the iden-
tified pathogenic TYR mutations are not specific to the 
Hungarian population, as they have been detected world-
wide in OCA patients [22, 29].
No pathogenic OCA2 mutation was identified in the 
examined Hungarian individuals, although one patient 
carried the common p.Arg305Trp polymorphism in het-
erozygous form. This variant has been associated with 
human eye color and might be an inherited biomarker of 
cutaneous cancer risk [28, 30].
Three mutation and a common polymorphisms were 
detected on the SLC45A2 gene. Two patients carried two 
heterozygous variants of the SLC45A2 gene previously 
described by our workgroup: the p.Gly409Asp missense 
and the p.Gln487* nonsense mutations [31]. Both muta-
tions are situated in transmembrane domains of the MATP 
protein (Uniprot: Q9UMX9). The locations of the muta-
tions suggest that they impair the transport function of the 
MATP protein. MATP dysfunction might cause an acidic 
melanosomal lumen, leading to incorrect incorporation 
of copper into tyrosinase. The reduced tyrosinase activity 
could lead to the development of the OCA phenotype [32]. 
Besides, the p.Leu374Phe polymorphism was detected in 
nine Hungarian OCA patients. This variant has a striking 
population distribution, exists almost exclusively in Euro-
peans, and has also been implicated in the development of 
different shades of hair, skin, and eye color [33].
Our results emphasize the importance of the parallel 
analysis of multiple genes for studying disease phenotypes. 
The OCA cases presented in this study and many other 
cases reported in the literature call our attention to the 
fact that clinical symptoms—which may overlap in many 
cases—are not sufficient for a diagnosis of different OCA 
forms: the molecular genetic investigation of all OCA 
genes is required to determine the subtype of the disease. 
The Hungarian OCA patients in this study exhibited iden-
tical clinical features (Table 1); however, molecular genetic 
investigation identified the OCA1 subtype in eight cases, 
the OCA4 subtype in two cases, and the molecular diagno-
sis was not clearly defined in three patients (Table 2). Even 
with these data, the genetic basis of the disease in seven 
patients carrying only one pathogenic TYR or SLC45A2 
mutation is still not completely explained. We wish to 
emphasize the screening of the non-pathogenic variants, 
which alone could not lead to the development of OCA, 
should be carried out in association with pathogenic vari-
ants that might have clinical significance. Further targeted 
sequencing of the genes involved in the syndromic OCA 
variants, including HPS and CHS, as well as genes involved 
in human pigmentation, is hoped elucidate the underlying 
disease-causing variant(s) [22].
Our results and previously reported studies suggest 
that, among the investigated genes, the majority of the 
mutations are located within the TYR gene [3, 4]. This 
result correlates well with the results obtained in other 
populations, as TYR mutations are the most common for 
OCA worldwide [1]. Screening of the TYR gene is, there-
fore, of primary importance for diagnostics. Mutations 
in the investigated Hungarian and in other previously 
reported OCA patients were found most frequently in 
exons 1 and 4 of the TYR gene [4]. In light of the fact that 
the majority of the identified TYR mutations are located 
within exon 1 and 4, we recommend screening these 
exons first.
According to our current knowledge, 10–25% of the 
isolated and syndromic OCA cases are not explained by 
paired, trans-oriented mutations in known genes [34, 35]. 
Based on our results and the results of previous studies 
[22], we suggest that screening non-Mendelian OCA-
associated genes might elucidate the causative genetic 
variant for these cases.
Conclusions
The genetic heterogeneity of OCA is extremely com-
plex: both rare mutations of Mendelian genes and com-
mon variants of non-Mendelian genes can contribute to 
the development of the disease. Our multi-gene study 
provides novel data for the genetic diversity of OCA in 
Hungarians and indicates that approaches that take this 
complexity into account, including large-scale studies, 
are needed to complete our understanding of the genetic 
heterogeneity of this disease.
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